Pombiliti 105 mg
As listed in the register: Pombiliti 105 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
105 mg ·
- Prescription only
- Digestion, stomach, diabetes and nutrition
- Active substance
- Cipaglucosidasum alfa
- Made by
- Amicus Therapeutics Switzerland GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Behandlung der Glykogenspeicherkrankheit Typ II (Morbus Pompe)
From the official label · 2026-09-30 · Swissmedic
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Amicus Therapeutics Switzerland GmbH |
|---|---|
| Active substance | Cipaglucosidasum alfa |
| Used in | Digestion, stomach, diabetes and nutrition |
| Strength | 105 mg |
| Classification | A16AB23 · Digestion, stomach, diabetes and nutrition |
| Dispensing (as stated by the register) | Abgabekategorie A |
| Name in the register | Pombiliti 105 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung |
| Packs | 1 Ampulle(n) · 10 Ampulle(n) · 25 Ampulle(n) |
| Zulassungsnummer | 67804 |
| Dosisstärke | 1 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.